Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (409)	4/6/2001 10:47:10 PM
From: The Dodgy Ticker	Respond to of 2243

In case you missed it, Peregrine Pharmaceuticals (Techniclone) has a new CEO, who is also its largest stock-holder. PPHM's debt is now owed to its CEO; little risk of default, IMO. I'll defer to the experts, but to me, PPHM is developing some very interesting technology. Friday April 6, 5:55 pm Eastern Time Peregrine Pharmaceuticals names Legere as CEO TUSTIN, Calif., April 6 (Reuters) - Peregrine Pharmaceuticals Inc. (NasdaqSC:PPHM - news) said on Friday it named Edward Legere as the cancer drug development company's president and chief executive. Legere, who will retain his seat on the company's board, immediately replaces John Bonfiglio, who resigned to pursue other opportunities, the company said in a statement. Legere has served as Peregrine's interim president and CEO since February, when Bonfiglio went on a leave of absence. Legere, who originally joined the board as a director in 1992, has been on the board during seven of the past nine years. He is currently the largest beneficial owner of the company's common stock. Legere's common stock ownership in Peregrine wasn't immediately available.